When was April Biotechnology founded?

April Biotechnology was founded in 2013.

Where is April Biotechnology located?

April Biotechnology is headquartered in Seoul, South Korea.

Who is the current CEO of April Biotechnology?

Cha Hun of April Biotechnology.

Is April Biotechnology a funded company?

April Biotechnology is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does April Biotechnology rank among its competitors?

April Biotechnology ranks 1648th amongst 3524 active competitors, of which 1217 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Biosciences, which secured $37.6M in Dec, 2024.

Who are the top competitors of April Biotechnology?

April Biotechnology's top competitors include Jazz Pharmaceuticals, BeiGene and Alexion. Among them, Senti Biosciences secured the most recent funding round in December, 2024.

April Biotechnology - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immunotherapies for auto-immune and cancer. It has albumin binder fusion platform SAFA , protein technology platform and Ex-12 helper phage antibody library technology to develop antibody drugs for solid tumors, endocrine disease, auto-immune disease, and infertility.

Website: aprilbio.com
Phone Number: +82 **********

Key Metrics

Founded Year

2013

Location

Seoul, South Korea

Stage

Public

Investors

Kolon Investments & 5 more

Ranked

1648^th among 3524 active competitors

Similar Companies

BeiGene & 1038 more

Exit Details

Public

View April Biotechnology's full profile

April Biotechnology got listed on Jul 28, 2022.

Click here to take a look at April Biotechnology's IPO in detail

April Biotechnology is a funded company. April Biotechnology has 6 institutional investors.

View details of April Biotechnology's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of April Biotechnology include Jazz Pharmaceuticals, BeiGene and Alexion. Here is the list of Top 10 competitors of April Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
7th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
8th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
9th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
10th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
1648th	April Biotechnology 2013, Seoul (South Korea), Public	Developer of immunotherapies for auto-immune and cancer	-	Kolon Investments, LB Investment & 4 others	34/100